novartis glp-1 receptor agonist weight management diabetes treatments GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 | Acta Diabetologica APhA 2025: GLP-1 Receptor Agonists

J Exp Med 2015

Recent solution NMR structural studies have provided detailed molecular models of the p53 transactivation domain in complex with both the FOXO4 forkhead domain and FOXO4-DRI, advancing understanding of the precise molecular interactions that enable selective senescent cell targeting in research applications

Incretins are carried through the circulation to their target tissue: the pancreatic beta cells

Synovial cells cotransfected with miRNA-125 mimics, and PARP2-siRNA had significantly lower expression of pro-inflammatory cytokines, MMP-1, p-PI3K, p-Akt, and p-mTOR in comparison with the negative groups

H.Brown-FrandsenK.KristensenP.MannJ